Laddar...
Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines
Our previous preclinical studies and a Phase I clinical trial DP6-001 have indicated that a polyvalent Env formulation was able to elicit broadly reactive antibody responses including low titer neutralizing antibody responses against viral isolates of subtypes A, B, C and AE. In the current report,...
Sparad:
| I publikationen: | Hum Vaccin Immunother |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Taylor & Francis
2017
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5718816/ https://ncbi.nlm.nih.gov/pubmed/28933684 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1380137 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|